Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) discovers, develops and commercializes RNA-targeted medicines for serious diseases, using antisense oligonucleotides and other nucleic-acid technologies to affect gene expression. Its marketed portfolio includes TRYNGOLZA and DAWNZERA, which it independently commercializes in… From the company’s description.
In fiscal 2025, Ionis Pharmaceuticals, Inc. reported revenue of $943.71M, up 33.8% from fiscal 2024, and a net loss of $381.39M. Its operating margin was −40.4%, and operations used $268.58M in cash. Over the twelve months to Jun 30, 2026, revenue was $874.09M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Ionis Pharmaceuticals, Inc. does
In the company’s own words
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) discovers, develops and commercializes RNA-targeted medicines for serious diseases, using antisense oligonucleotides and other nucleic-acid technologies to affect gene expression. Its marketed portfolio includes TRYNGOLZA and DAWNZERA, which it independently commercializes in the U.S.; WAINUA, developed and commercialized with AstraZeneca in the U.S.; and medicines commercialized by partners, including SPINRAZA and QALSODY. Its focus areas include neurology, cardiometabolic disease and selected rare diseases, and its pipeline includes wholly owned and partnered programs. Ionis operates as a biotechnology company with commercial medicines and research and development activities; the filing does not identify reportable business segments. The company reported $944 million in revenue for fiscal 2025 and had seven marketed medicines at year-end. It works with global pharmaceutical partners including AstraZeneca, Biogen, GSK, Novartis, Otsuka and Roche. Ionis was incorporated in 1989 and changed its name from Isis Pharmaceuticals in 2015. Its website is www.ionis.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CARLSBAD, CA
- Fiscal year end
- December
- CIK
- 874015
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Ionis Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Ionis Pharmaceuticals, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Ionis Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Ionis Pharmaceuticals, Inc.’s bonds, as funds hold them
Funds report holding 2 issues of Ionis Pharmaceuticals, Inc.’s debt, $319.76M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 1.75%, maturing 2028 to 2030.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Ionis Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Ionis Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Ionis Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”